Scarica l'app Stockscreener
0.9734
2.66%
-0.0266
Dopo l'orario di chiusura:
.97
-0.0034
-0.35%
Precedente Chiudi:
$1.00
Aprire:
$1.02
Volume 24 ore:
302.81K
Relative Volume:
0.33
Capitalizzazione di mercato:
$80.21M
Reddito:
$38.70M
Utile/perdita netta:
$-117.88M
Rapporto P/E:
-0.5726
EPS:
-1.7
Flusso di cassa netto:
$-92.84M
1 W Prestazione:
-1.87%
1M Prestazione:
+3.67%
6M Prestazione:
-38.00%
1 anno Prestazione:
-63.81%
Intervallo 1D:
$0.9655
$1.03
Intervallo di 1 settimana:
$0.95
$1.04
Portata 52W:
$0.81
$2.74
Adicet Bio Inc Stock (ACET) Company Profile
Nome
Adicet Bio Inc
Settore
Industria
Telefono
617-482-2333
Indirizzo
131 DARTMOUTH STREET, BOSTON
Confronta ACET con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACET
Adicet Bio Inc
|
0.9734 | 80.21M | 38.70M | -117.88M | -92.84M | -1.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-30 | Ripresa | Guggenheim | Buy |
| 2024-09-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-06-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-06-27 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-06-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-03-31 | Iniziato | SMBC Nikko | Outperform |
| 2022-03-08 | Iniziato | Truist | Buy |
| 2022-03-04 | Iniziato | Jefferies | Buy |
| 2021-05-18 | Iniziato | BTIG Research | Buy |
| 2021-04-23 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-14 | Iniziato | Canaccord Genuity | Buy |
| 2021-04-08 | Iniziato | Guggenheim | Buy |
| 2020-11-04 | Iniziato | B. Riley Securities | Buy |
| 2020-10-27 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-10-16 | Iniziato | Wedbush | Outperform |
Mostra tutto
Adicet Bio Inc Borsa (ACET) Ultime notizie
Adicet Bio’s SWOT analysis: gamma-delta T cell stock faces pivotal year - Investing.com Nigeria
Adicet Bio's SWOT analysis: gamma-delta T cell stock faces pivotal year - Investing.com
Healthy Upside Potential: Adicet Bio Inc (ACET) - SETE News
Adicet Bio Inc [ACET] Insider Activity: An Update for Investors - Knox Daily
Investor Alert: What’s Really Going On At Adicet Bio Inc (NASDAQ: ACET) - Stocks Register
Adicet Bio (NASDAQ:ACET) Earns Market Perform Rating from JMP Securities - MarketBeat
Brokerages Set Adicet Bio, Inc. (NASDAQ:ACET) PT at $7.50 - MarketBeat
Adicet Bio reports progress in clinical trial enrollments - MSN
HC Wainwright Reaffirms Neutral Rating for Adicet Bio (NASDAQ:ACET) - MarketBeat
Adicet Bio (NASDAQ:ACET) Earns “Market Perform” Rating from JMP Securities - Defense World
Top investors say Adicet Bio Inc (ACET) ticks everything they need - SETE News
Major Win – FDA Grants Fast Track Designation to Adicet Bio’s ADI-001 for Lupus Disease - geneonline
Adicet Bio (NASDAQ:ACET) Earns “Neutral” Rating from HC Wainwright - Defense World
Adicet Bio Inc [NASDAQ: ACET] Sees Increase in Stock Value - Knox Daily
Adicet Bio reports progress in clinical trial enrollments By Investing.com - Investing.com Australia
Adicet Bio Inc (ACET) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Adicet Bio Inc (ACET) Stock Price and Analyst Predictions - The News Heater
What is ACET’s price-to-sales ratio telling us about the company’s value? - US Post News
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement - Marketscreener.com
Revolutionary Lupus Treatment Gets FDA Fast-Track: Adicet's ADI-001 Could Transform Patient Care - StockTitan
JPMorgan Chase & Co. Boosts Stock Holdings in Adicet Bio, Inc. (NASDAQ:ACET) - Defense World
Adicet Bio Sparks Excitement with Major Stock Options Award for New Hires! - Mi Valle
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Adicet's New CMO Receives 750,000 Share Options Package as Company Bolsters Leadership - StockTitan
Adicet Bio doses first subject in Phase I trial of renal cell carcinoma therapy - MSN
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference - Business Wire
HC Wainwright & Co. Downgrades Adicet Bio (ACET) - MSN
Adicet Bio, Inc. (NASDAQ:ACET) Shares Sold by Jane Street Group LLC - Defense World
Geode Capital Management LLC Increases Position in Adicet Bio, Inc. (NASDAQ:ACET) - Defense World
Adicet Bio Provides Corporate Update - TradingView
Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones - Business Wire
Adicet Bio Advances First Gamma Delta CAR T Cell Therapy for Solid Tumors, Expands Autoimmune Trial - StockTitan
Adicet Bio, Inc. (NASDAQ:ACET) Stake Reduced by State Street Corp - Defense World
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Update - Defense World
Adicet Bio (NASDAQ:ACET) Stock Passes Below 200-Day Moving Average – Time to Sell? - Defense World
Adicet Bio (NASDAQ:ACET) Stock Price Crosses Below 200 Day Moving AverageWhat's Next? - MarketBeat
ACET Founder Acme Proposes Using Bitcoin Integration to Transform Thailand Economy - GlobeNewswire Inc.
Adicet Bio (NASDAQ:ACET) Earns Neutral Rating from HC Wainwright - Defense World
Adicet Bio, Inc. (NASDAQ:ACET) Shares Bought by Fmr LLC - Defense World
Adicet Bio begins trial for kidney cancer therapy By Investing.com - Investing.com Canada
Adicet Bio Advances with Phase 1 Trial of ADI-270 - TipRanks
Adicet Bio (NASDAQ:ACET) Receives Neutral Rating from HC Wainwright - MarketBeat
Adicet Bio begins trial for kidney cancer therapy - Investing.com
Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - BioSpace
ACET stock touches 52-week low at $0.89 amid market challenges By Investing.com - Investing.com South Africa
ACET stock touches 52-week low at $0.89 amid market challenges - Investing.com Canada
Adicet Bio names new Chief Medical Officer By Investing.com - Investing.com Australia
Adicet Bio Inc Azioni (ACET) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):